BioArctic, Eisai begin working on Leqembi’s brain-penetrant successor

22 Apr 2024
firstwordpharma.com
Phase 2Drug Approval
Partnered since 2005 to develop Alzheimer’s disease treatments, Eisai and BioArctic disclosed a new research collaboration for a next-generation therapy that will use the latter’s BrainTransporter technology to enable brain penetration.
The new programme comes as the partners’ first approved product, Leqembi (lecanemab-irmb), struggles to gain greater global traction, and shortly after a subcutaneous version of the anti-amyloid-beta antibody got hit with a regulatory setback.
Eisai and BioArctic will share costs for the research evaluation of BAN2802, which combines an undisclosed therapeutic with the BrainTransporter tech. According to the Swedish biotech, BrainTransporter can actively transport biologics across the blood-brain-barrier and has the potential to create faster and stronger efficacy of treatments targeted to the brain, while reducing the burden of treatment for patients.
The Japanese pharma has an option to license BAN2802 once the research collaboration has ended.
Boosting brain penetration might be the next evolution of Alzheimer’s treatments. Last month, Roche shared Phase II data of trontinemab, which uses the pharma’s Brainshuttle technology to bind to transferrin receptors on endothelial cells to smoothly cross the blood-brain-barrier and then home in on amyloid-beta plaques in the brain. The antibody demonstrated a rapid rate of plaque clearance that could rival Leqembi.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.